Related Experiment Video
Updated: Sep 11, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
In Silico Development of a Multi-epitope Vaccine Targeting TFDP3: A Novel Approach for Cancer Immunotherapy
Genilda Castro de Omena Neta1,2, Jose Wilson Batista da Silva Junior1, Rodger Marcel Lima Rocha1
1Federal University of Alagoas, Arapiraca, Alagoas, Brazil.
Abstract:
The increase in cancer incidence and mortality demonstrates the need for more effective anti-tumor therapies. Targeted therapies, such as cancer testicular antigens (CTAs), are promising as they are expressed in tumor cells but not in normal cells. TFDP3, a CTA expressed in cancers such as triple-negative breast cancer, prostate cancer, childhood T-cell lymphoblastic leukemia, and hepatocellular carcinoma, was chosen as a target for vaccine development. This study aimed to predict a multi-epitope vaccine based on TFDP3 using immunoinformatics tools to identify antigenic epitopes that interact with B lymphocytes, CD4+T lymphocytes, and CD8+T lymphocytes. Three epitopes from each lymphocyte type were selected, considering factors such as antigenicity, allergenicity, toxicity, IFN-γ induction, and population coverage. The vaccine also included adjuvants and ligands that ensure the stability and proper processing of the epitopes. The in-silico analysis revealed that the vaccine has favorable physicochemical properties, low homology with human proteins, and interactions with Toll-like receptors, ensuring stability. The population coverage world of the MHC class I and II epitopes were 93.55%. Additionally, the vaccine can be cloned and induce a robust immune response after three administrations. Despite the promising results, immunotherapy still faces challenges, such as tumor heterogeneity and immune evasion. In vitro and in vivo studies are necessary to assess the vaccine's efficacy and safety for future cancer treatments that express TFDP3.
Insights
This study developed a novel multi-epitope cancer vaccine targeting TFDP3, a cancer testicular antigen. In-silico analysis shows high population coverage and potential for a robust immune response against TFDP3-expressing cancers.
Area of Science:
- Oncology
- Immunology
- Bioinformatics
Background:
- Rising cancer incidence necessitates novel anti-tumor therapies.
- Targeted therapies using cancer testicular antigens (CTAs) show promise due to tumor-specific expression.
- TFDP3 is a CTA found in various cancers, including triple-negative breast cancer and hepatocellular carcinoma.
Purpose of the Study:
- To design a multi-epitope vaccine targeting TFDP3 using immunoinformatics.
- To identify and select potent T-cell and B-cell epitopes for vaccine development.
- To evaluate the vaccine's in-silico properties, including stability, immunogenicity, and population coverage.
Main Methods:
- Immunoinformatics tools were employed to predict antigenic epitopes from TFDP3.
- Epitopes were selected based on antigenicity, allergenicity, toxicity, and IFN-γ induction.
- In-silico analysis assessed vaccine physicochemical properties, homology, and interactions with Toll-like receptors.
Main Results:
- A multi-epitope vaccine construct targeting TFDP3 was computationally designed.
- Selected epitopes demonstrated favorable antigenicity and low predicted toxicity.
- The vaccine construct exhibited high world population coverage (93.55%) for MHC class I and II alleles.
- In-silico analysis indicated favorable stability and potential for inducing a robust immune response.
Conclusions:
- The in-silico designed TFDP3-based vaccine is a promising candidate for cancer immunotherapy.
- Further in vitro and in vivo studies are required to validate its efficacy and safety.
- This vaccine strategy holds potential for treating TFDP3-expressing cancers.
More Related Videos
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...